This webinar will cover general principles and modes of action for mRNA vaccines. It will also cover the production process including intermediates, raw materials, components of the drug substance, and drug product. The relationship of physicochemical aspects of DS and DP to quality attributes will be discussed.

The webinar will focus on:

I. mRNA Vaccines and Mode of Action
II. Characteristics of the mRNA Drug Substance
III. Nucleoside Analogues: Stability by design
IV. Poly A Tail: Dialing in another component of stability
V. mRNA Drug Substance (DS) Manufacture
VI. Manufacturing Process: Components of Purification
VII. Troubleshooting the Reaction
VIII. Drug Product Production: mRNA-loaded LNP

Subject area:
Biologics

Objectives (If applicable):
N/A

Target Audience (If applicable):
Suppliers and manufacturers of mRNA vaccine drug substances, contract manufacturing organizations, drug testing organizations, regulatory agencies, and QA/QC specialists.

Since the platform is amenable to other biologics outside of the vaccine space, such as cancer and enzyme replacement therapies, those interested in these biologics are also encouraged to attend.